Eastern Equine Encephalitis (EEE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032


 

Eastern equine encephalitis (EEE) is a rare yet grave infection resulting in encephalitis or brain inflammation. It is caused by the EEE virus (EEEV), transmitted through the bite of a mosquito carrying the virus. Considered one of the most severe forms of arboviral encephalitis in America, EEE affects individuals differently based on their age. Those over 50 and under 15 face the highest risk of severe illness. The onset of severe EEE cases is sudden, marked by intense headache, high fever, chills, and vomiting. These symptoms can progress to disorientation, seizures, encephalitis, and coma. Alarming statistics show that approximately one-third of EEE patients do not survive the infection. Those who do survive often experience varying degrees of brain damage. The EEE virus, classified within the Togaviridae family and alphavirus genus, is maintained through a cycle involving birds and primarily Culiseta melanura mosquitoes found in freshwater hardwood swamps. To date, no antiviral medication has demonstrated effectiveness against Eastern equine encephalitis. Supportive care remains the primary approach, with severe cases often necessitating admission to intensive care units and ventilatory assistance. Healthcare professionals in areas with elevated risk of EEE transmission should consider this infection when presented with aseptic meningitis or encephalitis cases. Any suspected instances should be promptly reported to local health authorities. The differential diagnosis encompasses other viral encephalitides like measles, mumps, echovirus, and the less probable Creutzfeldt–Jakob disease. The fatality rate for EEE is estimated to be as high as 41% and around 50% of affected patients will experience some form of neurological impairment. Factors that predict poor outcomes include severe hyponatremia, abnormal electroencephalograms, and high initial cerebrospinal fluid pleocytosis. Although these findings might indicate inflammatory markers, it's intriguing that patients treated with corticosteroids tend to fare worse than those who aren't treated with them.

Thelansis’s “Eastern Equine Encephalitis (EEE) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Eastern Equine Encephalitis (EEE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Eastern Equine Encephalitis (EEE) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Eastern Equine Encephalitis (EEE) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Eastern Equine Encephalitis (EEE) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Comments

Post a Comment

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Image
  Acne vulgaris, a prevalent pilosebaceous unit inflammatory skin disorder, follows a persistent course. Typically presenting as papules, pustules, or nodules, it primarily occurs on the face but can also impact the upper arms, trunk, and back. The development of acne results from the sebaceous glands' heightened sensitivity to normal androgen levels, aggravated by Cutibacterium acnes (formerly known as Propionibacterium acnes), a bacterial species that triggers inflammation. The pathogenesis of acne vulgaris involves a complex interplay of factors such as the activation of sebaceous glands by androgens, imbalances in the pilosebaceous follicle microbiome, and cellular immune responses. Genetic predisposition and dietary influences also contribute to the condition's onset and progression. The initial stage is the micro-comedo, a small plug primarily composed of corneocytes in the lower follicular infundibulum. Microcomedones evolve into various acne lesions, including closed co...
Read more

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
 Herpes simplex virus (HSV) causes an infection that affects the external genitalia, anal region, mucosal surfaces, and skin in other body parts. Herpes simplex virus is a ubiquitous, host-adapted pathogen that causes various disease states. There are two types of HSV with two distinct DNA viruses, type 1 (HSV-1) and type 2 (HSV-2). Both the types are closely related but differ epidemiologically. HSV-1 is traditionally associated with orofacial disease by affecting the mouth and lips with fever blisters and cold sores, whereas HSV-2 is associated traditionally with genital disease infecting genitals and rectum area with sores and is classified as STD (sexually transmitted disease). As HSV-1 is associated with genital infections more often than HSV-2, lesion location is not necessarily of viral type. HSV can spread through direct contact. Almost 80% of Herpes simplex infections are asymptomatic, while symptomatic infections can be characterized by significant morbidity and recurrenc...
Read more

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Image
Thelansis’s “HR+/HER2- Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HR+/HER2- Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of HR+/HER2- Breast Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs. HR+/HER2- Breast Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model,...
Read more